Chapter 34: Antiviral Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about treating an infection, for you listening, there's this underlying expectation of straightforward, almost clean warfare.

Right, like a targeted strike.

Exactly.

Think about a bacterial infection.

You get strep throat, you take an antibiotic, and that drug acts like a targeted missile.

It just seeks out the bacteria, glows up its cell wall, and leaves your own cells completely alone.

It's, you know, it's satisfying.

It is because, well, bacteria are their own separate entities.

They have their own internal machinery, their own protective walls, their own metabolic processes.

So from a pharmacological standpoint, you can destroy them without destroying yourself.

But then you step into the world of virology and suddenly that clean warfare is just, well, it's gone.

We're looking at a pharmacological landscape that is incredibly fraught.

So welcome to the Deep Dive.

Glad to be here.

For you, our dedicated student tuning in, our mission today is to conquer a very specific, very dense piece of material.

We are diving into Chapter 34, Antiviral Drugs, from Lippincott Illustrated Reviews, Pharmacology, the seventh edition.

It's a heavy chapter.

It really is.

And we're going to proceed in the exact order of the chapter, translating all this dense pharmacology into plain, student -friendly English.

We want to connect the foundational physiology directly to the drug targets.

Right, because if you understand the why behind the mechanisms,

the side effects and the clinical uses just naturally fall into place.

Exactly.

Okay, let's unpack this, starting with the central challenge of antiviral pharmacology.

Why are viruses so uniquely difficult to treat compared to, say, a bacterial infection?

Well, what's fascinating here is that viruses are, by their very definition,

obligate intracellular parasites.

Meaning they have to live inside our cells.

Exactly.

They don't have a cell wall to target.

They don't have a cell membrane.

They don't even carry out their own metabolism.

They are basically just rogue packets of genetic code.

Wow.

So to survive and multiply, they have to physically hijack the host cellular factories.

It's essentially a hostile takeover of a factory.

The virus sneaks in the back door, changes all the locks, and forces your own workers to stop making what you need and start building millions of new viruses instead.

It's a perfect analogy.

And here's the rub.

If you just, you know, bomb the factory to stop the bad guys, well, you've destroyed your own infrastructure.

You've killed the host cell.

Finding a drug selective enough to only hurt the virus while leaving your own host cells completely intact is a monumental task.

It really is.

And to complicate the picture even further, clinical symptoms usually appear very late.

Right.

By the time you actually feel sick, by the time you have a fever or a cough,

massive widespread viral replication has already occurred.

So the damage is already done.

Exactly.

Giving someone a drug that blocks viral replication at that late stage often has incredibly limited effectiveness.

The horse has already left the barn.

Makes sense.

If you look at figure 34 .1 in the text, it serves as the chapter's roadmap.

It organizes the few successful antiviral drugs we do have by their targets.

Right.

It breaks them down into respiratory, hepatic, herpes, and CMV, and finally HIV.

So let's start right at the top of that roadmap with respiratory viral infections.

We're talking specifically about influenza A and B and respiratory syncytial virus, or

With these, timely intervention is absolutely everything because the virus multiplies so rapidly in the lungs.

The clock is basically ticking the second they enter your system.

Let's look at the flu first.

Okay.

So for influenza, we rely heavily on a class of drugs known as neuraminidase inhibitors.

You probably know the most famous one, osultamivir, which goes by the brand name tomiflu.

Oh yeah, everyone knows tomiflu.

Right.

And there's also xanamivir.

Now, to understand how they work, we have to look at the virus's exit strategy.

Okay, I love this part.

Influenza viruses use a specific enzyme called neuraminidase, which sits on the surface of the host cell membrane.

Its entire job is to release newly formed virions from the host cell so they can go infect adjacent cells.

I always picture neuraminidase as a pair of molecular scissors.

Yeah, exactly.

The newly built virus is physically tethered to the outside of the host cell, and it uses these scissors to cut the final tether and break free.

So by giving a patient a neuraminidase inhibitor, you're essentially confiscating the scissors.

You're taking them away, yeah.

The newly formed viruses stay glued to the cell surface.

They literally can't spread.

So they just sit there and die.

Essentially, yes.

Yeah.

Now, figure 34 .2 shows the fate of these drugs in the body.

Pharmacokinetically, they arrive at the site differently.

Losultamivir is an oral prodrug, meaning you swallow it and your liver has to chemically Right.

Xanavivir, on the other hand, is inhaled directly into the respiratory tract.

But despite the different delivery methods, figure 34 .2 shows they share the exact same fate.

They're both excreted completely unchanged in your urine.

That's fascinating.

But the absolute critical factor here is the timeline, right?

Oh, absolutely.

They must be given within 24 to 48 hours of your symptoms starting.

Right, because if you wait until day four, the factory has already produced all the viruses it's going to produce.

Compensating the scissors at that point just doesn't help.

Exactly.

And we also have to watch out for the side effects.

Oh, right.

Osultamivir is infamous for causing GI discomfort and nausea, so you absolutely want to tell your patient to take it with food.

Yes.

And with Xanavivir, because you're inhaling a powder directly into irritated lungs, it can trigger bronchospasm.

So if a patient has asthma or COPD, you have to be extremely cautious.

Good to know.

Now, the book also has a historical note about the adamantins.

Yes, amantidine and remantidine.

Historically, they targeted influenza A by blocking a viral ion channel, but viruses are highly adaptable.

They mutate.

Widespread viral resistance means those drugs are basically obsolete.

They're no longer recommended in the U .S.

Which perfectly illustrates the constant arms race we're in.

OK, let's talk about RSV.

This is particularly dangerous for infants.

The go -to heavy hitter here is a drug called ribavirin.

Yes, ribavirin.

It's a synthetic guanosine analog, and it's used for severe RSV in immunosuppressed infants, usually delivered via an aerosol mask.

Wait, let me stop you there.

A synthetic guanosine analog.

That essentially means it's a counterfeit building block, right?

That is exactly what it is.

The virus thinks it's picking up a standard piece of genetic material to build its RNA, but we've slipped it a useless fake.

Right.

It works by inhibiting the formation of guanosine triphosphate, which prevents viral messenger RNA from being capped.

It essentially jams the viral RNA polymerase machinery.

OK, but I need to push back on this, or at least ask a question.

If you read the text, ribavirin causes dose -dependent anemia.

And even more terrifying, it says it can rapidly deteriorate an infant's respiratory function.

Yeah, that's true.

If a drug can literally make breathing worse in a baby who is already fighting a severe respiratory infection, why use it at all?

It's a really stark example of risk versus reward.

We only deploy ribavirin in severe, life -threatening cases where the virus itself is almost certainly fatal without intervention.

So it's a last resort?

Exactly.

The risk of the drug is high, yes.

But the risk of the untreated virus is a guaranteed catastrophe.

It requires meticulous, continuous monitoring in a hospital setting.

And speaking of severe risks, the book describes figure 34 .4, which is just this stark, harsh visual of a crossed -out fetus.

It's a very clear warning.

It's a reminder that ribavirin is strictly contraindicated in pregnancy due to massive teratogenic effects.

It causes birth defects.

A vital safety parameter.

Now, let's shift gears from viruses that hit the lungs hard and fast to something far more insidious.

The hepatic viruses.

Hepatitis B and C.

Right.

These are chronic invaders that settle into your liver and slowly destroy your hepatocytes and your liver cells over years and decades.

The scope of the problem is huge.

Figure 34 .5 is a bar chart that reveals something really interesting.

Hepatitis B, which is a DNA virus, affects roughly a million people in the U .S.

But hepatitis C, which is an RNA virus, is way more prevalent, affecting over 3 million people.

It's a massive public health issue.

Let's start with how we treat hepatitis B.

For a long time, the cornerstone was interferons.

Interferons are naturally occurring glycoproteins in your immune system that, true to their name, interfere with the virus's ability to infect cells.

The pharmacological version used is often a pedulated interferon.

Pedulated.

I love explaining this concept.

Figure 34 .6 illustrates this perfectly.

Pedulation means they attach a massive molecule called polyethylene glycol, or PEG, to the drug.

Which fundamentally changes its kinetics.

Right.

I like to think of this as putting a giant bulky winter coat on the drug molecule.

It makes the molecule so large that the kidneys have a really hard time filtering it out.

It delays absorption and lengthens its duration in the body.

Precisely.

It allows for once a week dosing.

But the trade -off is the side -effect profile.

It is brutal.

Brutal is an understatement.

The text points out severe bone marrow suppression,

profound fatigue, and massive neurotoxicity.

We're talking severe depression and behavioral changes.

It's an agonizing regimen, so we also have oral agents for Hep B.

Like lamividine, adephavir, and enticavir.

Exactly.

Now, to connect the physiology to the side effects here, let's look at adevera.

Right.

Adephavir is highly nephrotoxic.

It damages the kidneys.

And why is that?

Because it's excreted primarily via the kidneys.

It concentrates there.

Now the text notes that lamividine and adephavir are largely no longer recommended.

Why not?

Due to high rates of viral resistance and lower efficacy.

That makes enticavir the preferred oral option today.

Okay, so that's Hep B.

But Hep C, this is where it gets really interesting.

Oh, it's a complete revolution in medicine.

To understand the Hep C drugs, we have to look at the virus's complex life cycle.

It doesn't just build one protein at a time.

It translates a massive,

continuous polyprotein.

Right, like a long, uncut string of proteins.

Exactly.

And to be useful, that giant string has to be chopped up into active pieces by a viral enzyme called a protease.

Once they are chopped up, they form a replication complex.

So researchers developed direct -acting antivirals, or DAAs, to target these specific steps.

The first group are the NS3 -NS4A protease inhibitors.

These stop the viral proteins from being chopped up.

Right, you can spot these because they end in the suffix previr, like peritaprivir.

But there's a huge risk with the previrs, right?

They heavily interact with the CYP3A enzymes in the liver.

Yes.

CYP3A interactions are a massive concern.

If a patient is on other medications metabolized by that pathway, you can get severe drug toxicity or failure.

So we also have the NS5B polymerase inhibitors.

These target the RNA copying machine itself.

And those end in Bouvier, like Sosa's Bouvier.

And this is the best part.

If you look at figure 34 .7, there's a table showing how modern therapy works.

It completely avoids those toxic interferons we talked about earlier.

Thank goodness.

Instead, it relies on DAA combinations.

We hit the hep C virus at multiple life cycle stages,

simultaneously blocking the protease and the polymerase at the same time.

By doing that, tailored to the specific viral genotype, you prevent resistance.

We don't just treat hep C now.

We cure it.

It's just incredible.

Okay, moving on from the liver.

Let's transition to viruses that hide out in our nervous system and cells.

The herp is virus family and cytomegalovirus or CMV.

Right.

Because they lie dormant, they require incredibly specific cellular activation to be stopped.

Let's look at a cyclover, the classic drug for herpes simplex and varicella zoster.

The mechanism of a cyclover is just elegant.

A cyclover is a guanosine analog, right?

Another counterfeit building block.

But it requires a specific key to work.

Figure 34 .8 lays this out.

A cyclover is inactive when it enters the host cell.

It requires a viral enzyme,

specifically viral thymidine kinase, to be monophosphorylated.

I marvel at this every time I read it.

The drug is essentially harmless to human cells.

It just floats around doing nothing until the virus itself hands it the key, that first phosphate group, to turn it into an active weapon.

Yes.

The virus seals its own fate.

Once it has that first phosphate, host cellular kinases add two more, now it's fully phosphorylated.

And then it mimics a DNA building block, gets incorporated by the viral DNA polymerase, and causes premature chain termination.

Boom.

Viral replication stops.

It's brilliant.

But for CMV, a cyclover doesn't cut it, right?

Right.

CMV is a heavier hitter, often affecting immunocompromised patients, causing issues like severe retinitis.

For CMV, we use drugs like Cidifivir.

No, Cidifivir does not depend on viral enzymes.

Exactly.

It doesn't need viral thymidine kinase, which makes it great for resistance strains.

But that lack of specificity comes with a huge cost.

Figure 34 .10 shows this perfectly.

It's just a stark illustration of a damaged kidney icon.

Cidifivir carries a massive risk of nephrotoxicity.

It's so severe that you have to co -administer oral probenicid and IV saline just to protect the kidneys while the drug is in the system.

Wow.

And then there's Foskarnet.

Figure 34 .11 maps this one out.

Unlike the others, Foskarnet is not a purine or pyrimidine analog, it's a pyrophosphate derivative.

Right.

It reversibly inhibits viral polymerases without needing to be phosphorylated at all.

But the side effects are intense.

Nephrotoxicity, of course, but also hypocalcemia.

Yeah, that's because Foskarnet chelates divalent -cations.

Meaning it acts like a chemical magnet, grabbing onto the calcium in your blood and stripping it out of circulation.

That sudden drop in calcium can cause severe issues.

Which is why Gansaclover and its oral prodrug, Valgansaclover, are often used.

Figure 34 .12 shows these are essentially acyclover analogs but with much greater CMV activity.

Valgansaclover is the highly bioavailable oral version.

But again, a massive warning label here.

It causes severe dose -dependent neutropenia.

Wiping out your white blood cells.

Exactly.

And it is highly carcinogenic and teratogenic.

We also briefly want to mention Pensaclover and Phamsaclover, summarized in Figure 34 .13.

They're used for HSV and VZV, with Phamsaclover being the oral prodrug of Pensaclover.

Okay.

We are arriving at the final section.

The most complex viral target in the chapter.

The treatment of HIV infection using antiretroviral therapy or ARTA.

This is a completely different beast because HIV utilizes multiple unique enzymes requiring a multi -drug cocktail approach.

If you look at Figure 34 .20, it is a dramatic sweeping graph.

It shows AIDS deaths absolutely plummeting after 1995.

Because that was the year combination therapy was introduced.

It literally changed history.

So let's break down the cocktail.

First up, the NRTIs.

Yeah.

Nucleoside and nucleotide reverse transcriptase inhibitors.

To understand these, let's look at the physiology.

HIV is a retrovirus.

It uses an enzyme called reverse transcriptase to turn its viral RNA into DNA.

And the NRTIs are analogs, but they uniquely lack a 3 -hydroxyl group.

Exactly.

When the viral reverse transcriptase tries to build DNA, it grabs this fig building block.

But because that 3 -hydroxyl group is missing, no phosphatidester bond can form.

It's like trying to snap a Lego onto a piece that has a completely flat bottom.

I love that.

You just can't attach the next piece.

Chain elongation terminates immediately.

But there are adverse effects.

Because while they prefer viral enzymes,

NRTIs can interact with our own host mitochondrial DNA polymerase.

Leading to mitochondrial toxicity.

The older drugs like didanosine and stavidine hurt the mitochondria so badly they cause peripheral neuropathy and lipoatrophy, wasting away of fat.

Which is why they are rarely used now.

We also have abacavir, which carries a very specific fatal hypersensitivity risk.

You have to do genetic screening for the HLA -B5701 allele before prescribing it.

Mandatory screening, yes.

Okay, next up are the protease inhibitors, or PIs.

You can spot these by the navir suffix.

Like adazanavir or darunavir?

Right.

Their mechanism is straightforward.

They inhibit HIV aspartyl protease, also known as retropepsin.

Just like with hep C, the virus makes a big polyprotein and the protease chops it up.

If you inhibit that, the viral particles still bud off the cell, but they are non -infectious immature virions.

They're duds.

But the adverse effects of PIs, wow.

Figures 34 .21 and 34 .22 paint a picture of a metabolic nightmare.

Yeah, hypertriglyceridemia, severe hyperglycemia, and fat accumulation at the base of the neck.

What's often called a buffalo hump.

And the drug interactions are just as wild.

Figures 34 .23 and 34 .24 show that PIs heavily inhibit the CYP450 system in the liver.

They jam at the liver's disposal system.

So if you take them with a statin, like dendastatin, the statin levels skyrocket and cause rhabdomyolysis muscle breakdown.

If you take it with fentanyl, it causes respiratory depression.

And it goes the other way, too.

If a patient takes St.

John's wort, which is an over -the -counter herbal supplement, it actually induces CYP450.

It speeds the disposal system up.

Right, and that destroys the PI's efficacy.

The drug gets chewed up before it can fight the HIV.

It's a pharmacological minefield.

Okay, let's round out the cocktail with entry and integrase inhibitors.

Infuvritide is an entry inhibitor.

It binds to the viral GP41 protein, preventing the virus from fusing with the host membrane.

But it has to be injected subcutaneously.

And then there are the integrase inhibitors, the NSTIs, which end in Tegravir.

These block the insertion of proviral DNA right into the host genome.

Crucial mechanism.

But there's a huge interaction to note for you studying this.

They chelate with antacids.

They bind to the polyvalent cations in antacids.

So if a patient takes Tums, the HIV drug forms a clump in the gut and doesn't get absorbed.

You have to separate the doses.

Good catch.

Finally, we have the pharmacokinetic enhancers, or boosters, ritonavir and cobasistat.

Wait, I have a question here.

If ritonavir is technically an older antiviral, why is it used as a booster instead of a main treatment?

And proteasat doesn't even have anti -HIV activity.

It's one of the most clever things in pharmacology.

They intentionally leverage a side effect.

Okay, explain that.

We just talked about how protease inhibitors shut down the CYP3A liver enzymes.

Well, ritonavir and cobasistat are profoundly potent CYP3A inhibitors.

So by giving a very low dose of these drugs, they stop the liver from breaking down the actual primary PI, or integrase inhibitor.

They act like chemical bodyguards.

They boost the levels of the main drug, allowing the patient to only take a pill once a day, and it prevents the virus from mutating to escape it.

Exactly.

It's brilliant.

That is amazing.

Okay, to solidify this knowledge, let's rapid fire through the chapter's specific practice questions to prove how the physiology answers the clinical scenarios.

Ready?

Let's do it.

A 24 -year -old patient comes in with genital hopies.

What is the answer?

Velocet clover.

You wouldn't use Cetofovir or Gansaclover.

Those are for CMV.

And Xanamivir is for the flu.

Right.

A hepatitis B patient develops severe nephrotoxicity.

Which drug caused it?

That's Adephavir.

Remember, renal excretion.

Love it.

Which hepatitis C drug inhibits the membranous web platform?

That would be your NS5A inhibitors.

Okay, which HIV drug chillates with polyvalent -cations, like antacids?

B -integrase inhibitors, like clovzogravirs.

And finally, which drug acts as a PK enhancer without having any antiviral activity of its Covizestan.

Perfect.

So what does this all mean for you, the listener?

Well, looking at the overarching theme of this chapter, from herpes to hep C to HIV,

we've learned to use the virus's own mechanics against it.

Tricking viral thymidine kinase in herpes, or jamming the unique molecular scissors in HIV and hep C.

But viruses are the ultimate survival machines.

They mutate constantly.

Which leaves us with a provocative thought to mull over.

Are we forever locked in a molecular arms race, relying on our ability to combine drugs faster than the viruses can mutate their enzymes, or will we find a way to step out of the arms race entirely?

Food for thought.

Thank you for joining us for this session.

A warm thank you from the Last Minute Lecture Team, and we'll see you in the next Deep Dive.